SCRATCH Pharmacovigilance
SCRATCH Pharmacovigilance is recorded as a service provider in 13 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 13 of 13 trials · Latest update first
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide. A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom)
Sponsor Universitaetsklinikum Wuerzburg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
GUIDANCE – A multicenter phase II trial of maintenance durvalumab and olaparib after standard 1st-line treatment (carboplatin/cisplatin, etoposide, durvalumab) in HRD-positive extensive-disease small-cell lung cancer
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
- Not reported
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms who have relapsed after one or more prior therapies, including subjects with primary refractory disease
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A prospective, randomized, evaluator- and subject blinded, multi-center investigation to assess efficacy and safety of three different dosages of the same injection pattern of LetibotulinumtoxinA in the treatment of moderate and severe horizontal forehead lines
Sponsor Croma-Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
Sponsor SymbioPharm GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin
Sponsor Acousia Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for SCRATCH Pharmacovigilance?
The 2026-10-09 snapshot links SCRATCH Pharmacovigilance to 13 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Medical expertise, Medical monitoring service, Medical writing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for SCRATCH Pharmacovigilance?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Neurology, Respiratory. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to SCRATCH Pharmacovigilance conducted?
The linked trials record locations in 18 countries, including Germany, Poland, Austria, Bulgaria, Netherlands. These are trial locations, not confirmed office locations or countries where SCRATCH Pharmacovigilance delivered services.
What can this page tell me about SCRATCH Pharmacovigilance's trial experience?
Browse 13 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under SCRATCH Pharmacovigilance. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- SCRATCH Pharmacovigilance GmbH & Co. KG